Because we found that the RAR-α antagonist BMS 195614 was not specific, we aimed to select another commercially available RAR inhibitor to compare its biological activity to the effects of norbixin in our in vitro model of AMD. The gene discussed is RARA; the disease is age-related macular degeneration.